Sensei brings on new CMO as it eyes phase 2 immuno-oncology trial | Digital Science

Biotherapeutics named Ildiko Csiki, M.D., Ph.D., as its new chief medical officer. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.

She takes over for Edward Garmey, M.D., an oncology drug development consultant and former chief medical officer at Cerulean Pharma, who was serving as Sensei’s acting since March.

The Gaithersburg, Maryland-based Sensei, previously known as Panacea Pharmaceuticals, is currently awaiting full 1 clinical data this fall from its lead immunotherapy candidate, SNS-301, a bacteriophage viral vector that targets an embryonic antigen expressed on the surface of more than 20 different types of adult cancer cells.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

In June, alongside the annual meeting of the American Society of Clinical Oncology in Chicago, Sensei published phase 1 data assessing safety and immunogenicity of SNS-301 in patients with biochemically recurrent prostate cancer.

In 12 patients receiving an average of 10 doses over the 15-month study, early results showed that SNS-301 was well tolerated, with a favorable safety profile across all dose levels, the company said. No dose-limiting toxicities were observed at the three evaluated dose levels, and all patients experienced dose-dependent, specific cellular immune responses, including B-cell and T-cell responses.

Web Hosting

RELATED: Panacea, renamed as Sensei Bio, appoints former X4 executive as CEO

In addition, six of eight patients showed improvements in prostate-specific antigen levels, or the amount of time it took for PSA levels to double. Sensei is currently planning to begin enrollment in a phase 2 efficacy by the end of the year, which Csiki will help lead as CMO.

At Inovio, Csiki helped advance DNA-based cancer immunotherapies based on T cell vaccines by overseeing clinical programs, strategy and regulatory submissions.

Before that, she served as a senior director of oncology clinical development and as a Keytruda development lead at Merck, as well as a director of clinical development at GlaxoSmithKline, focusing on lymphoma and other oncology programs. Csiki also served as an assistant professor at the Perelman Cancer Center at the University of Pennsylvania, with a translational laboratory researching thoracic malignancies.

You might also like More from author

Comments are closed.